Format

Send to

Choose Destination
Clin Exp Rheumatol. 2010 Mar-Apr;28(2 Suppl 58):S55-62. Epub 2010 Jun 24.

Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.

Author information

1
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. dkhanna@mednet.ucla.edu

Abstract

Pulmonary disease is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Recent well-designed trials in SSc-associated interstitial lung disease (SSc-ILD) have provided important insights regarding outcome measures and trial design. Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review.

PMID:
20576216
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Clinical and Experimental Rheumatology
Loading ...
Support Center